(redirected from Leukotriene receptor antagonist)
Also found in: Medical.
LTRALeukotriene Receptor Antagonist
LTRALong-Term Response Action
LTRALong Term Remedial Action
LTRALong-Term Repopulating Ability (stem cells)
LTRALow Temperature Requirement A (protein)
LTRALong-Term Rental Assistance Program (City of Miami Community Development; Miami, FL)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
KEYWORDS: Anti-leukotrienes, leukotriene receptor antagonists, Montelukast, CysLT, receptors, asthma, randomized controlled trial.
Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients.
Back, "Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease," The Journal of Allergy and Clinical Immunology, vol.
Montelukast, a oncedaily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial.
[16-20] Since inhaled or oral corticosteroids have not been shown to attenuate leukotriene production in vivo [21], therefore, a leukotriene receptor antagonist in combination with inhaled corticosteroid may confer additional benefits and could be the best combination.
Bisgaard et al., "Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years," Pediatrics, vol.
For patients who have an inadequate response to an inhaled SABA before exercise and/or patients who require an inhaled SABA daily or more frequently, a controller agent such as an inhaled corticosteroid or a leukotriene receptor antagonist is recommended.
Effects of a cysteinyl leukotriene receptor antagonist on eosinophil recruitment in experimental allergic rhinitis.
Prevention of severe premenstrual asthma attacks by leukotriene receptor antagonist. J Allergy Clin Immunol.
This minority of asthmatics likely represents the fraction of asthmatics that would improve significantly from anti-leukotriene drugs, including a 5-lipoxygenase inhibitor or leukotriene receptor antagonist. These drugs are not completely efficacious in blocking this pathway, however, and a strategy of decreasing the total burden of leukotriene production further by supplementing with omega-3-rich fish oil is rational.
Pathophysiological role of mast cells in collagen-induced arthritis: Study with a cysteinyl leukotriene receptor antagonist, montelukast.